Design and biological evaluation of cell-penetrating peptide-doxorubicin conjugates as prodrugs

Molecular Pharmaceutics

Volumn 10, Issue 2, 2013, Pages 488-499

  Nasrolahi Shirazi, Amir ^a   Tiwari, Rakesh ^a   Chhikara, Bhupender S ^a   Mandal, Dindyal ^a   Parang, Keykavous ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

anticancer; cell penetrating peptides; cellular uptake; cyclic peptides; doxorubicin

Indexed keywords

CATENATED DNA; CELL PENETRATING PEPTIDE; CYCLOPEPTIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; PRODRUG; RW 4 PEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; BREAST ADENOCARCINOMA; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; COLORECTAL CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; COVALENT BOND; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG HYDROLYSIS; DRUG RETENTION; DRUG SCREENING; DRUG STABILITY; DRUG UPTAKE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LEUKEMIA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OVARY ADENOCARCINOMA; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

CELL-PENETRATING PEPTIDES; DOXORUBICIN; DRUG DESIGN; MESALAMINE; MOLECULAR STRUCTURE; PRODRUGS;

EID: 84873372857     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp3004034     Document Type: Article

References (39)

1. Vincenzi, B.; Frezza, A. M.; Santini, D.; Tonini, G. New therapies in soft tissue sarcoma Expert Opin. Emerging Drugs 2010, 15, 237-248
2. Quigley, G. J.; Wang, A. H.; Ughetto, G.; van der Marel, G.; van Boom, J. H.; Rich, A. Molecular structure of an anticancer drug-DNA complex: daunomycin plus d(CpGpTpApCpG) Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 7204-7208 (Pubitemid 11189441)
3. Patel, D. J.; Kozlowski, S. A.; Rice, J. A. Hydrogen bonding, overlap geometry, and sequence specificity in anthracycline antitumor antibiotic.DNA complexes in solution Proc. Natl. Acad. Sci. U.S.A 1981, 78, 3333-3337 (Pubitemid 11059284)
4. Gottesman, M. M. Mechanisms of drug resistance Annu. Rev. Med. 2002, 53, 615-627
5. Longely, D. B.; Johnston, P. G. Molecular mechanisms of drug resistance J. Pathol. 2005, 205, 275-292 (Pubitemid 40227997)
6. Stavrovskaya, A. A. Cellular mechanisms of multidrug resistance of tumor cells Biochemistry 2000, 65, 95-106
7. Kratz, F. DOXO-EMCH (INNO-206): The first albumin binding prodrug of doxorubicin to enter clinical trials Expert Opin. Invest. Drugs 2007, 16, 855-866 (Pubitemid 46882358)
8. Tang, Y.; McGoron, A. J. Combined effects of laser-ICG photothermotherapy and doxorubicin chemotherapy on ovarian cancer cells J. Photochem. Photobiol., B 2009, 97, 138-144
9. Raoul, J. L.; Heresbach, D.; Bretagne, J. F.; Ferrer, D. B.; Duvauferrier, R.; Bourguet, P.; Messner, M.; Gosselin, M. Chemoembolization of hepatocellular carcinomas a study of the biodistribution and pharmacokinetics of doxorubicin Cancer 1992, 70, 585-590
10. Rahman, A.; Carmichael, D.; Harris, M.; Roh, J. K. Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes Cancer. Res. 1986, 46, 2295-2299 (Pubitemid 16120685)
11. Chhikara, B. S.; St. Jean, N.; Mandal, D.; Kumar, A.; Parang, K. Fatty acyl amide derivatives of doxorubicin: Synthesis and in vitro anticancer activities Eur. J. Med. Chem. 2011, 46, 2037-2042
12. Chhikara, B.S.; Mandal, D.; Parang, K. Synthesis, anticancer activities, and cellular uptake studies of lipophilic derivatives of doxorubicin succinate J. Med. Chem. 2012, 55, 1500-1510
13. Takemura, G.; Fujiwara, H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management Prog. Cardiovasc. Dis. 2007, 49, 330-352 (Pubitemid 46295436)
14. Ayla, S.; Seckin, I.; Tanriverdi, G.; Cengiz, M.; Eser, M.; Soner, B. C.; Oktem, G. Doxorubicin induced nephrotoxicity: protective effect of nicotinamide Int. J. Cell Biol. 2011, 390238
15. Seelig, A.; Gatlik-Landwojtowicz, E. Inhibitors of multidrug efflux transporters: their membrane and protein interactions Mini-Rev. Med. Chem. 2005, 5, 135-151 (Pubitemid 40305726)
16. Yang, X.; Deng, W.; Fu, L.; Blanco, E.; Gao, J.; Quan, D.; Shuai, X. Folate functionalized polymeric micelles for tumor targeted delivery of a potent multidrug-resistance modulator FG020326 J. Biomed. Mater. Res., Part A 2008, 86, 48-60 (Pubitemid 351799487)
17. Chavanpatil, M. D.; Khdair, A.; Gerard, B.; Bachmeier, C.; Miller, D. W.; Shekhar, M. P. V.; Panvam, J. Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux Mol. Pharmaceutics 2007, 4, 730-738 (Pubitemid 350004273)
18. Sadava, D.; Coleman, A.; Kane, S. E. Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells J. Liposome Res. 2002, 12, 301-309 (Pubitemid 36008393)
19. Ibsen, S.; Zahavy, E.; Wrasdilo, W.; Berns, M.; Chan, M.; Esener, S. A novel doxorubicin prodrug with controllable photolysis activation for cancer chemotherapy Pharm. Res. 2010, 27, 1848-1860
20. Chhikara, B. S.; Parang, K. Development of cytarabine prodrugs and delivery systems for leukemia treatment Expert Opin. Drug Delivery 2010, 7, 1399-1414
21. Wang, Y.; Li, L.; Jiang, W.; Yang, Z.; Zhang, Z. Synthesis and preliminary antitumor activity evaluation of a DHA and doxorubicin conjugate Bioorg. Med. Chem. Lett. 2006, 16, 2974-2977
22. Kumar, S. A.; Peter, Y. A.; Nadeau, J. L. Facile biosynthesis, separation and conjugation of gold nanoparticles to doxorubicin Nanotechnology 2008, 19, 495101
23. You, J.; Zhang, G.; Li, C. Exceptionally high payload of doxorubicin in hollow gold nanosphere for near-infrared light triggered drug release ACS Nano 2010, 4, 1033-1041
24. Massing, U.; Fuxius, S. Liposomal formulations of anticancer agents: selectivity and effectiveness Drug Resist. Updates 2000, 3, 171-177 (Pubitemid 30616502)
25. Derossi, D.; Joliot, A. H.; Chassaing, G.; Prochiantz, A. The third helix of the Antennapedia homeodomain translocates through biological membranes J. Biol. Chem. 1994, 269, 10444-10450 (Pubitemid 24198241)
26. Derossi, D.; Chassaing, G.; Prochiantz, A. Trojan peptides: the penetratin system for intracellular delivery Trends Cell Biol. 1998, 8, 84-87 (Pubitemid 28056816)
27. Meyer-Losic, F.; Quinonero, J.; Dubois, V.; Alluis, B.; Dechambre, M.; Michel, M.; Cailler, F.; Fernandez, A. M.; Trouet, A.; Kearsey, J. Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell) J. Med. Chem. 2006, 49, 6908-6916 (Pubitemid 44749756)
28. Ché, C.; Yang, G.; Thiot, C.; Lacoste, M.-C.; Currie, J.-C.; Demeule, M.; Régina, A.; Béliveau, R.; Castaigne, J.-P. New angiopep modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration J. Med. Chem. 2010, 53, 2814-2824
29. Lindgren, M.; Rosenthal-Aizman, K.; Saar, K.; Eiriksdottir, E.; Jiang, Y.; Sassian, M.; Ostlund, P.; Hallbrink, M.; Langel, U. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide Biochem. Pharmacol. 2006, 71, 416-425 (Pubitemid 43077076)
30. Zhu, S.; Hong, M.; Zhang, L.; Tang, G.; Jiang, Y.; Pei, Y. PEGylated PAMAM dendrimer-doxorubicin conjugates: In vitro evaluation and in vivo tumor accumulation Pharm. Res. 2010, 27, 161-174
31. Lee, J.-Y.; Choi, Y.-S.; Suh, J.-S.; Kwon, Y.-M.; Yang, V. C.; Lee, S.-J.; Chung, C.-P.; Park, Y.-J. Cell-penetrating chitosan/doxorubicin/TAT conjugates for efficient cancer therapy Int. J. Cancer 2011, 128, 2470-2480
32. Shi, N.-Q.; Gao, W.; Xiang, B.; Qi, X.-R. Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage Int. J. Nanomed. 2012, 7, 1613-1621
33. Aroui, S.; Ram, N.; Appaix, F.; Ronjat, M.; Kenani, A.; Pirollet, F.; De, Waard, M. Maurocalcine as a non toxic drug carrier overcomes doxorubicin resistance in the cancer cell line MDA-MB 231 Pharm. Res. 2009, 28, 836-845
34. Mandal, D.; Nasrolahi Shirazi, A.; Parang, K. Cell-penetrating homochiral cyclic peptides as nuclear-targeting molecular transporters Angew. Chem., Int. Ed. 2011, 50, 9633-9637
35. Nagy, A.; Schally, A. V.; Armatis, P.; Szepeshazi, K.; Halmos, G.; Miyazaki, M.; Jungwirth, A.; Horvath, J. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2- pyrrolinodoxorubicin, a derivative 500-1000 times more potent Proc. Nat. Acad. Sci. U.S.A. 1996, 93, 7269-7273 (Pubitemid 26243538)
36. Nasrolahi Shirazi, A.; Mandal, D.; Tiwari, R. K.; Guo, L.; Lu, W.; Parang, K. Cyclic peptide-capped gold nanoparticles as drug delivery systems Mol. Pharmaceutics 2012, 10.1021/mp300448k
37. Swift, L. P.; Rephaeli, A.; Nudelman, A.; Philips, D. R.; Cutts, S. M. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death Cancer 2006, 66, 4893-4871
38. Tsang, W. P.; Chau, S. P. Y.; Kong, S. K.; Fung, K. P.; Kwok, T. T. Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis Life Sci. 2003, 73, 2047-2058 (Pubitemid 36930039)
39. Kim, H. S.; Lee, Y. S.; Kim, D. K. Doxorubicin exerts cytotoxic effects through cell cycle arrest and fas-mediated cell death Pharmacology 2009, 84, 300-309